Stock HOTH HOTH THERAPEUTICS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hoth Therapeutics, Inc.

Equities

HOTH

US44148G2049

Delayed Nasdaq
Other stock markets
 01:30:00 18/05/2024 am IST 		5-day change 1st Jan Change
1.18 USD -0.84% Intraday chart for Hoth Therapeutics, Inc. +0.84% -18.06%
28/03 Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
19/03 Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Hoth Therapeutics to Attend EF Hutton Annual Global Conference, May 15, 2024
PR
Hoth Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Hoth Therapeutics Announces Exercise of Warrants for $4.2 Million Gross Proceeds
PR
Hoth Therapeutics' Wholly Owned Subsidiary Merveille.ai, Advances AI-Driven Discovery for Obesity Treatment
PR
Wall Street Set to Open Lower Ahead of Two-Day Fed Meeting; Housing Starts Surge Higher Than Expected
MT
Hoth Therapeutics Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
PR
Hoth Therapeutics, Inc. Announces Positive Data In Completed Study of Alzheimer's Disease Pre-Clinical Treatment with HT-ALZ
CI
Hoth Therapeutics Engages Altasciences to Perform Key Study for HT-KIT Cancer Fighting Therapeutic
PR
Hoth Therapeutics to Attend BIO CEO and Investor Conference, February 26-27, 2024
PR
HC Wainwright Starts Hoth Therapeutics With Buy Rating, $4 Price Target
MT
Hoth Therapeutics Shares Rise 14% After FDA Clearance for HT-001 Trial Amendments
DJ
Hoth Therapeutics Announces it Received FDA Approval to Expand HT-001 Clinical Trial to Treat Severely Ill Patients
PR
Hoth Therapeutics Receives FDA Approval to Expand HT-001 Clinical Trial to Treat Severely III Patients
CI
Hoth Therapeutics Gets University of Miami Approval to Enroll Patients in Skin Toxicities Treatment Trial; Shares Rise
MT
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial For Cancer Patients of HT-001 at University of Miami
PR
Hoth Therapeutics Announces Expansion of FDA Cleared First-In-Human Clinical Trial for Cancer Patients of HT-001 At University of Miami
CI
Hoth Therapeutics Announces it Has Successfully Completed Manufacturing of its Cancer fighting HT-KIT for IND-Enabling Studies
PR
Hoth Therapeutics Announces Successfully Completed Manufacturing of its Cancer Fighting HT-KIT for Ind-Enabling Studies
CI
Hoth Therapeutics to Advance HT-KIT After Positive Feedback From FDA
MT
Hoth Therapeutics Announces Successful Completion of Pre-IND Meeting with FDA Regarding Development of Hoth's Cancer Fighting HT-KIT
PR
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. HOTH Stock
  4. News Hoth Therapeutics, Inc.
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW